It turns out that investor opposition to Takeda’s $62 billion buyout of Shire comes down to blood. Investors are concerned that competition to Shire’s hemophilia drugs for blood disease cut its revenues so much that it will make the deal unsustainable.
The Financial Times, citing sources, reported that during a recent investor meeting, Takeda CEO Christophe Weber was pressed on how sustainable sales from Shire’s hemophilia unit will be in the face of competition from new generation drugs.
The unit accounts for a quarter of the Ireland-based drugmaker’s revenues, but analysts have said that they expect Roche’s Hemlibra, which is now under FDA priority review for a label expansion, will quickly erode much of Shire’s sales, the Financial Times reported. Unlike hemophilia drugs currently on the market, Hemlibra is not expected to require patients to undergo daily or weekly infusions of replacement Factor VIII.
“We continue to expect Hemlibra to become the new standard of care in the treatment of haemophilia A … and currently model peak sales of $5 billion for the product,” Jefferies analyst Ian Hilliker, told the newspaper.
Hemlibra is currently approved only for treating patients who develop factor VIII inhibitors during treatment but Roche is seeking a label expansion to those patients without the inhibitors, a much larger patient population. Data from a recent study showed Hemlibra significantly cut bleeding incidents in those patients.
Adding to its appeal is the fact that Roche has priced Hemlibra at $450,000, a significant discount to Shire’s Adynovate, a long-lasting replacement Factor VIII treatment, which bears a price tag of about $537,000 a year.
Weber tried to reassure doubtful investors, the Financial Times said, by insisting that Takeda built the impact from pending competition into its financial model for the deal.
But they also are worried about the potential for new gene-based treatments under development by Pfizer and others to grab market share if approved. These treatments are designed to fix the genetic problem that underlies the disease. While acknowledging Takeda is not going to be a leader in gene therapy, Weber pointed out the gene technology is complicated to develop, the Financial Times reported.
By Eric Palmer
Source: Fierce Pharma
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.